Revelation Biosciences announces development plan, partnership initiatives

Résumé détaillé
Revelation Biosciences (REVB) announced a strategic shift designed to accelerate development of Gemini, its proprietary therapeutic candidate designed to restore the body’s…
Revelation Biosciences (REVB) announced a strategic shift designed to accelerate development of Gemini, its proprietary therapeutic candidate designed to restore the body's natural inflammatory balance through multiple biological pathways. The strategy includes advancing a streamlined Phase 2a clinical study in patients with stage 2 or 3 acute kidney injury, AKI, to generate safety and efficacy data more rapidly and at substantially lower cost, while pursuing strategic partnerships and licensing opportunities to support Gemini's development and expand its commercial potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)




